Stock Symbol:   

Stoxline Mobile
Home  |  Stock Charts  |  Showcases  |  Stock Ranks  |  Options  |  ETFs  |  Educations  |  Forex Crypto

Acasti Pharma Inc. (ACST)

0.4202   -0.015 (-3.4%) 03-24 10:47
Open: 0.44 Pre. Close: 0.435
High: 0.44 Low: 0.42
Volume: 16,076 Market Cap: 19(M)

Technical analysis

as of: 2023-03-24 10:14:35 AM
Stoxline posted a NEUTRAL today, same as yesterday. Current trend continues, but could change at anytime. It is not a good time to buy or sell.
Target: Six months: 0.64     One year: 0.75
Support: Support1: 0.4    Support2: 0.33
Resistance: Resistance1: 0.55    Resistance2: 0.64
Pivot: 0.45
Moving Average: MA(5): 0.44     MA(20): 0.47
MA(100): 0.54     MA(250): 0.74
MACD: MACD(12,26): -0.1     Signal(9): -0.1
Stochastic oscillator: %K(14,3): 36.1     %D(3): 38.9
RSI: RSI(14): 31.5
52-week: High: 1.35  Low: 0.34
Average Vol(K): 3-Month: 161 (K)  10-Days: 49 (K)

Price, moving averages and Bollinger Bands

Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and NEUTRAL in mid-long term.
[ ACST ] has closed above bottom band by 22.5%. Bollinger Bands are 54.4% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 5 bars. This is a sign that the market may be about to initiate a new trend.

Stock Price Prediction

Update at 5:00pm EST
If tomorrow: Open lower Open higher
High: 0.48 - 0.48 0.48 - 0.49
Low: 0.41 - 0.42 0.42 - 0.42
Close: 0.43 - 0.44 0.44 - 0.44

Company Description

Acasti Pharma Inc., a biopharmaceutical company, engages in the development and commercialization of pharmaceutical products for cardiovascular diseases. It is evaluating strategic partnerships for the clinical development of CaPre. The company was incorporated in 2002 and is headquartered in Laval, Canada.

Headline News

Mon, 13 Mar 2023
Acasti Pharma Inc. Centralizes Marketplace for Shares on the Nasdaq with Voluntary Delisting from TSX Venture Exchange - Yahoo Finance

Wed, 08 Mar 2023
Acasti Pharma to Participate in Oppenheimer 33rd Annual ... - Benzinga

Tue, 28 Feb 2023
Acasti Pharma Recognizes Rare Disease Day - PR Newswire

Wed, 15 Feb 2023
Acasti Pharma Inc. (NASDAQ:ACST) Q3 2023 Earnings Call Transcript - Yahoo Finance

Thu, 29 Dec 2022
Acasti Pharma Inc. (NASDAQ:ACST) Q2 2023 Earnings Call Transcript - Yahoo Finance

Wed, 28 Dec 2022
Acasti Announces Preliminary Topline Results Met All Outcome ... - GlobeNewswire

Financial Analysis

Price to Book Value: Neutral
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Price to Earnings: Underperform
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Discounted cash flow: Outperform
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Return on Assets: Neutral
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Return on Equity: Neutral
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Debt to Equity: Neutral
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Free Technical Analysis Charts

Stock Basics & Statistics

Exchange:  NASDAQ
Sector:  Healthcare
Industry:  Biotechnology
Shares Out. 45 (M)
Shares Float 36 (M)
% Held by Insiders 20.2 (%)
% Held by Institutions 0.1 (%)
Shares Short 304 (K)
Shares Short P.Month 163 (K)

Stock Financials

EPS -0.34
EPS Est Next Qtl 0
EPS Est This Year -0.74
EPS Est Next Year -0.77
Book Value (p.s.) 2.17
Profit Margin (%) 0
Operating Margin (%) 0
Return on Assets (ttm) -8.3
Return on Equity (ttm) -16.7
Qtrly Rev. Growth 0
Gross Profit (p.s.) 0
Sales Per Share 0
EBITDA (p.s.) -0.34
Qtrly Earnings Growth 0
Operating Cash Flow -16 (M)
Levered Free Cash Flow -6 (M)

Stock Valuations

PE Ratio -1.32
PEG Ratio 0
Price to Book value 0.2
Price to Sales 0
Price to Cash Flow -1.24

Stock Dividends

Dividend 0
Forward Dividend 0
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.
Your Ad Here
StockChart iOS
StoxlineLite iOS
StoxlineLite iOS
OptionCalc iOS
StockChart Android
StoxlineLite Android
StoxlinePro Android
OptionCalc Android
(c) 2006-2022 | Contact us           
Data and information is provided for informational purposes only, and is not intended for trading purposes. Neither nor its data provider shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon. By accessing the web site, a user agrees not to redistribute the information found therein.